Simply Wall St.
Will 2026 FDA Decisions on Afrezza and FUROSCIX Redefine MannKind's (MNKD) Narrative
📊
AI Sentiment
Positive
7/10
- Home
- MNKD
MNKD
MannKind Corporation
as of 01-22-2026 11:44am EST
$5.90
+$0.18
+3.24%
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | DANBURY |
| Market Cap: | 1.8B | IPO Year: | 2004 |
| Target Price: | $10.08 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.10 | EPS Growth: | 23.47 |
| 52 Week Low/High: | $3.38 - $6.51 | Next Earning Date: | 02-25-2026 |
| Revenue: | $313,787,000 | Revenue Growth: | 17.43% |
| Revenue Growth (this year): | 21.4% | Revenue Growth (next year): | 25.03% |
Stock Insider Trading Activity of MannKind Corporation (MNKD)
Castagna Michael
Sell
Chief Executive Officer
MNKD Dec 16, 2025
Avg Cost/Share
$6.00
Shares
21,310
Total Value
$127,860.00
Owned After
2,504,792
SEC Form 4
Castagna Michael
Sell
Chief Executive Officer
MNKD Dec 12, 2025
Avg Cost/Share
$6.00
Shares
20,806
Total Value
$124,836.00
Owned After
2,504,792
SEC Form 4
Castagna Michael
Sell
Chief Executive Officer
MNKD Dec 2, 2025
Avg Cost/Share
$5.57
Shares
107,920
Total Value
$601,114.40
Owned After
2,504,792
SEC Form 4
Thomson David
Sell
EVP Genl Counsel & Secretary
MNKD Dec 2, 2025
Avg Cost/Share
$5.57
Shares
147,780
Total Value
$823,134.60
Owned After
841,719
SEC Form 4
Singh Sanjay R
Sell
EVP Technical Operations
MNKD Nov 14, 2025
Avg Cost/Share
$5.03
Shares
18,777
Total Value
$94,448.31
Owned After
455,211
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Castagna Michael | MNKD | Chief Executive Officer | Dec 16, 2025 | Sell | $6.00 | 21,310 | $127,860.00 | 2,504,792 | |
| Castagna Michael | MNKD | Chief Executive Officer | Dec 12, 2025 | Sell | $6.00 | 20,806 | $124,836.00 | 2,504,792 | |
| Castagna Michael | MNKD | Chief Executive Officer | Dec 2, 2025 | Sell | $5.57 | 107,920 | $601,114.40 | 2,504,792 | |
| Thomson David | MNKD | EVP Genl Counsel & Secretary | Dec 2, 2025 | Sell | $5.57 | 147,780 | $823,134.60 | 841,719 | |
| Singh Sanjay R | MNKD | EVP Technical Operations | Nov 14, 2025 | Sell | $5.03 | 18,777 | $94,448.31 | 455,211 |
Latest MannKind Corporation News
MNKD Breaking Stock News: Dive into MNKD Ticker-Specific Updates for Smart Investing
Zacks
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
📈
AI Sentiment
Highly Positive
9/10
Insider Monkey
MannKind Corporation (MNKD) Reveals 2026 Growth Drivers
📈
AI Sentiment
Highly Positive
9/10
Compare MNKD vs Leading Stocks
See how MNKD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MNKD MannKind Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.